

![]() |
Challenges and solutions for clinical development of new antibacterial agents: Results of a survey among pharmaceutical industry professionals |
|
Authors | ||
Published in | Antimicrobial Agents and Chemotherapy. 2015, vol. 59, no. 7, p. 3695-99 | |
Abstract | As the number of antibacterial medicines in the pipeline remains low, we anonymously surveyed pharmaceutical industry professionals on challenges and solutions for clinical development of these agents. Challenges were reported primarily as financial and regulatory. For multi-drug resistant organisms, there are needs for rapid diagnostic tests, new regulatory guidance, and adaptation of endpoints/trial designs. Regulators and public-private initiatives are addressing these challenges, to help ensuring that proposed solutions have the support of all involved stakeholders. | |
Keywords | Clinical trials, clinical development, antibacterial agent, multi-drug resistant organisms, regulatory, clinical trial design, pathogen-based trial, indication-based trial, pharmaceutical companies | |
Identifiers | DOI: 10.1128/AAC.00638-15 PMID: 25918147 | |
Full text | ||
Structures | ||
Research group | Epidémiologie et contrôle de la résistance aux antibiotiques (866) | |
Project | Autre: IMI grant agreement n° 115523 [Combatting Bacterial Resistance in Europe -- COMBACTE] | |
Citation (ISO format) | BETTIOL, Esther Odile et al. Challenges and solutions for clinical development of new antibacterial agents: Results of a survey among pharmaceutical industry professionals. In: Antimicrobial Agents and Chemotherapy, 2015, vol. 59, n° 7, p. 3695-99. doi: 10.1128/AAC.00638-15 https://archive-ouverte.unige.ch/unige:73786 |